- Home
- GBR vs HCWB Comparison
GBR vs HCWB Comparison
Compare GBR & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | HCWB |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.7M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GBR | HCWB |
|---|---|---|
| Price | $0.75 | $0.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 89.6K | ★ 21.9M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $155,000.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.67 | $0.25 |
| 52 Week High | $1.78 | $17.80 |
Technical Indicators
Market Signals| Indicator | GBR | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 39.00 |
| Support Level | N/A | $0.25 |
| Resistance Level | $0.87 | $0.78 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 11.96 | 55.61 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.